Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Capital Expenditures: 2015-2025

Historic Capital Expenditures for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $8,000.

  • Seres Therapeutics' Capital Expenditures fell 93.80% to $8,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $313,000, marking a year-over-year decrease of 73.18%. This contributed to the annual value of $380,000 for FY2024, which is 95.24% down from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Capital Expenditures is $8,000, which was down 95.00% from $160,000 recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Capital Expenditures registered a high of $4.1 million during Q3 2021, and its lowest value of $8,000 during Q3 2025.
  • Moreover, its 3-year median value for Capital Expenditures was $129,000 (2024), whereas its average is $779,818.
  • Per our database at Business Quant, Seres Therapeutics' Capital Expenditures surged by 6,100.00% in 2021 and then crashed by 98.48% in 2024.
  • Quarterly analysis of 5 years shows Seres Therapeutics' Capital Expenditures stood at $1.6 million in 2021, then soared by 119.33% to $3.5 million in 2022, then crashed by 74.66% to $877,000 in 2023, then crashed by 89.74% to $90,000 in 2024, then plummeted by 93.80% to $8,000 in 2025.
  • Its Capital Expenditures was $8,000 in Q3 2025, compared to $160,000 in Q2 2025 and $55,000 in Q1 2025.